International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationLong-Term Outcomes After Maximal Surgical Resection and Intraoperative Electron Radiotherapy for Locoregionally Recurrent or Locoregionally Advanced Primary Renal Cell Carcinoma
Introduction
In the United States, approximately 58,240 patients were diagnosed with cancer of the kidney or renal pelvis in 2010 (1). The majority of patients with this disease present with clinically localized renal cell carcinoma (RCC) and are candidates for potentially curative nephrectomy. However, some patients present with locoregionally advanced disease of borderline resectability. In addition, 1% to 3% of patients experience isolated locoregional (LR) recurrence in the retroperitoneal soft tissue and/or nodal basins after nephrectomy 2, 3, 4, 5. The optimal management of isolated LR recurrent disease remains unknown, given its relative infrequency. In carefully selected patients with resectable LR recurrent disease, salvage surgery is associated with long-term survival in only a small portion of patients 2, 3, 4, 5, 6, 7, 8, 9. In the setting of salvage or primary surgery, margin status was reported to be an important prognostic factor for survival 4, 10. However, a wide resection of tumor is often unachievable due to its close proximity or frank invasion into adjacent unresectable structures such as major vessels and/or vertebral bodies. Therefore, in patients with LR recurrence or LR advanced primary RCC of borderline resectability, it is appropriate to consider additional LR therapies adjunct to surgery to optimize LR control and survival.
Since 1989, we have treated selected patients with isolated LR recurrence after nephrectomy or LR advanced primary RCC with a multimodality approach consisting of perioperative external beam radiotherapy (EBRT), maximal resection, and intraoperative electron radiotherapy (IOERT). In 1994, we reported favorable early outcomes in an initial cohort of patients (11). In addition, we have reported high rates of local control and acceptable toxicity with this multimodality approach for patients with other LR advanced primary or LR recurrent abdominal and pelvic tumors 12, 13, 14, 15, 16, 17. Here we report long-term outcomes on an expanded series of patients with LR recurrence or LR advanced primary RCC treated with a multimodality approach incorporating IOERT.
Section snippets
Methods and Materials
The prospective departmental IORT database was searched for patients with RCC treated with IOERT at Mayo Clinic, Rochester, MN. Inclusion criteria included primary or recurrent RCC treated with surgery and IOERT to LR disease as a component of potentially curative therapy. Exclusion criteria included surgery and IOERT to a distant metastatic site for palliation of symptoms only. Twenty-two consecutive patients treated between 1989 and 2005 met the above criteria and were included in this
Results
Patient characteristics are detailed in Table 1. Three patients had LR advanced primary disease with extensive retroperitoneal nodal involvement, pancreas involvement, or nephrectomy with positive margins at an outside institution. Nineteen patients had an LR recurrence in the retroperitoneal soft tissue and/or lymph nodes at a median interval of 2.0 years (range, 0.7–13.7 years) after nephrectomy (Fig. 1). Eighteen patients were treated for first recurrence and 1 patient was treated for a
Discussion
The optimal management of LR recurrent or LR advanced primary RCC is unknown. In selected patients with LR recurrence, salvage surgery has been performed 2, 3, 4, 5, 6, 7. However, in many patients, a wide margin resection is difficult to achieve because tumor is intimately associated with critical, unresectable structures. Therefore, despite resection of all gross disease, patients are at high risk for further relapse and death 2, 3, 4, 5, 6, 7. In an effort to optimize LR control for patients
Conclusion
To our knowledge, our study represents the largest series examining a potential utility of the multimodality therapy consisting of perioperative EBRT, maximal surgical resection, and IOERT for patients with LR recurrent or LR advanced primary RCC. With mature follow-up, this treatment approach was associated with a low rate of LR recurrence, acceptable toxicity, and long-term survival in a significant number of patients. This regimen warrants further investigation to better define appropriate
References (29)
- et al.
Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy
J Urol
(2000) - et al.
Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma
J Urol
(2009) - et al.
Outcome of surgical treatment of isolated local recurrence after radical nephrectomy for renal cell carcinoma
J Urol
(2002) - et al.
Isolated local recurrence of renal cell carcinoma after radical nephrectomy: Experience with 10 cases
Urology
(2003) - et al.
Management of isolated renal fossa recurrence following radical nephrectomy
J Urol
(2005) - et al.
Experience with fossa recurrence of renal cell carcinoma
J Urol
(1992) - et al.
Therapy of locally recurrent renal cell carcinoma after nephrectomy
J Urol
(1996) - et al.
Preoperative external beam radiotherapy followed by cytoreductive surgery and intraoperative radiotherapy for locally advanced primary or recurrent renal malignancies
J Urol
(1994) - et al.
Use of intraoperative electron beam radiotherapy in the management of retroperitoneal soft tissue sarcomas
Int J Radiat Oncol Biol Phys
(2002) - et al.
Radical pelvic resection and intraoperative radiation therapy for recurrent endometrial cancer: Technique and analysis of outcomes
Gynecol Oncol
(2006)
Intraoperative irradiation for locally recurrent colorectal cancer in previously irradiated patients
Int J Radiat Oncol Biol Phys
Combined modality therapy including intraoperative electron irradiation for locally recurrent colorectal cancer
Int J Radiat Oncol Biol Phys
Complications of intraoperative radiation therapy
Int J Radiat Oncol Biol Phys
Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma
Radiother Oncol
Cited by (19)
Systematic Review of the Management of Local Kidney Cancer Relapse
2018, European Urology OncologyCurrent Role of Radiotherapy for Renal-Cell Carcinoma: Review
2017, Clinical Genitourinary CancerLocal Recurrence After Curative Surgical Treatment of Renal Cell Cancer: A Study of 91 Patients
2016, Clinical Genitourinary CancerCitation Excerpt :To enhance the local therapeutic effect, patients at high risk of positive surgical margins in our study were offered IORT (18.7%). IORT, in addition to surgery, for LR has been proposed to improve local tumor control, especially in patients with LR who have a high risk of incomplete resection.21,22 Seventeen patients underwent surgery combined with IORT, 13 (76%) of whom had negative margins at the final pathologic examination.
Kidney and Ureteral Carcinoma
2015, Clinical Radiation OncologyRadiotherapy for renal-cell carcinoma
2014, The Lancet OncologyCitation Excerpt :Accordingly, findings from other retrospective studies have shown a significant reduction in local recurrence rate after adjuvant irradiation of pT3 tumours to conventionally fractioned doses of 41·4–63·0 Gy.37–39 Hallemeier and colleagues40 reported an update on 22 patients with primary locally advanced (14%) or recurrent (86%) disease who were treated with a multimodality approach of preoperative radiotherapy, surgical resection and intraoperative radiotherapy. Locoregional control at 5 years exceeded 60%, which compared favourably with historical series of patients given surgery alone for recurrent disease.
Outcomes in a multi-institutional cohort of patients treated with intraoperative radiation therapy for advanced or recurrent renal cell carcinoma
2014, International Journal of Radiation Oncology Biology PhysicsCitation Excerpt :Similar to treating RCC metastases with radiosurgery, the large single-fraction dose provided by IORT may be particularly useful against a tumor that is commonly thought to be relatively radiation resistant (7). The addition of IORT in primary and recurrent settings has been previously reported in small single-institution cohorts, with encouraging initial results (8-12). In this study, we sought to examine prognostic factors and disease outcomes in a large pooled multi-institutional cohort of patients who received IORT for RCC.
Conflict of interest: none.